50 Patients
Abbott’s study examined 50 hepatitis C patients, who were given a combination of the antiviral drugs ABT-450, ABT-072,
ritonavir and ribavirin. The 17 who were treated before showed a 47 percent cure rate, while those who had never been treated had a rate of between 93 and 95 percent, Abbott said.
Abbott is in the process of splitting into a diversified products company led by its medical device division, and a drug company, to be called AbbVie.